STOCK TITAN

Syndax Pharmaceuticals Inc - SNDX STOCK NEWS

Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.

Overview

Syndax Pharmaceuticals Inc (SNDX) is a commercial-stage biopharmaceutical company that is reimagining cancer care with an innovative pipeline of combination therapies. Focused in the field of oncology and biotechnology, the company is renowned for its specialized approach in developing novel treatments targeted at various cancer indications and immune disorders. By capitalizing on decades of scientific discovery and clinical expertise, Syndax continues to strengthen its position in a competitive landscape through careful research and data-driven development programs.

Innovative Pipeline and Core Product Candidates

The company has built a reputation on its dedication to research and development, with an intriguing pipeline that includes:

  • Revumenib: An oral, small molecule menin inhibitor developed to target acute leukemias, particularly those driven by KMT2A-rearrangements or mutant NPM1. Revumenib is designed to interfere with the menin-KMT2A interaction, an essential pathway in leukemogenesis, and demonstrates significant promise in altering the course of aggressive blood cancers.
  • Axatilimab (Niktimvo): A monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) to modulate inflammation and fibrosis. Axatilimab has been positioned as a first-in-class therapy in chronic graft-versus-host disease (GVHD), offering a new therapeutic option for patients who have exhausted multiple lines of systemic treatment.

These candidates are supported by comprehensive clinical programs and regulatory milestone achievements that emphasize both innovation and scientific rigor.

Clinical Development and Regulatory Milestones

Syndax has strategically advanced its product candidates through rigorous clinical trials and development programs designed to meet clear medical needs. The clinical data for revumenib and axatilimab have played a central role in building the company’s credentials. The approach involves:

  • Robust evaluation of efficacy and safety across varied dosing regimens.
  • Strategic collaborations with key clinical and research institutions to enhance trial designs.
  • Adherence to stringent regulatory guidelines which have culminated in FDA approvals and breakthrough designations for specific indications.

The company’s achievements underscore a strong commitment to not only advancing its pipeline but also ensuring that each candidate meets high standards of scientific validity and doctor-patient safety.

Business Model and Strategic Partnerships

Syndax integrates a multifaceted business model that combines active clinical development with innovative funding strategies and commercial readiness. A recent synthetic royalty funding agreement illustrates the strategic infusion of capital that enables the company to maintain its research trajectory while progressing toward profitability. In addition, collaboration with industry peers helps amplify the value proposition of its approved therapies and supports a robust commercial launch infrastructure. This collaborative model provides the framework for continuous research, expansive trials, and wider therapeutic application beyond the initial clinical focus.

Commitment to Research, Expertise, and Market Position

At its core, Syndax Pharmaceuticals is driven by excellence in research and a dedication to transforming patient care through targeted therapies. The company leverages deep scientific expertise to tackle intricate molecular pathways underlying cancer, such as the menin-KMT2A interaction in acute leukemias and the CSF-1R mediated inflammatory cascade in chronic GVHD. This technical focus is supported by:

  • Expert-led clinical trial programs utilizing cutting-edge methodologies.
  • A strong network of academic, clinical, and industry partners who contribute to substantial peer validation and real-world experience.
  • An unwavering commitment to bridging the gap between innovative science and accessible patient treatments.

By establishing itself as a trusted name in the biopharmaceutical community, Syndax remains a key player among companies with a mission centered on improved clinical outcomes and long-term patient benefits.

Key Takeaways for Investors and Analysts

Syndax Pharmaceuticals’ strategic approach is marked by:

  • Robust clinical data supporting its core product candidates.
  • A balanced business model that efficiently integrates clinical innovation with commercial execution.
  • Ongoing validation through regulatory milestones and industry collaborations.
  • An emphasis on addressing significant unmet medical needs in oncology and immunotherapy.

The company’s well-crafted scientific strategy and commitment to data integrity make it a compelling subject of study for investors and industry analysts seeking a deep-dive into advanced cancer therapeutics. Syndax exemplifies thoroughness in clinical research, prudence in financial management, and a forward-thinking approach to redefining standards of patient care in oncology.

Conclusion

In summary, Syndax Pharmaceuticals Inc embodies the convergence of innovative science and strategic commercial execution. Its portfolio of targeted therapies, underpinned by rigorous clinical research and regulatory achievements, positions the company as a noteworthy contender in the biopharmaceutical space. With deep expertise in niche molecular pathways and a commitment to transforming treatment paradigms, Syndax continues to enhance its influence across the oncology landscape, ensuring that meaningful scientific advancements translate into lasting patient benefits.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company, announced on June 3, 2024, that it granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees. These awards were given under the Company's 2023 Inducement Plan on June 1, 2024. The stock options will vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly thereafter over 36 months. The vesting is contingent upon the employee's continued service with Syndax.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
-
Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on cancer therapies, has appointed Aleksandra Rizo, M.D., Ph.D., to its Board of Directors effective May 15, 2024. Dr. Rizo, who has extensive experience in clinical development and commercialization of hematology drugs, will replace Dr. Briggs Morrison. Dr. Rizo currently serves as President and CEO of Vividion and has previously held leadership roles at Geron and Celgene Syndax is transitioning to a commercial-stage organization with the potential launch of two new treatments, Revumenib and Axatilimab, in 2024. Dr. Rizo will contribute her expertise as Syndax aims for long-term success in clinical and corporate development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
management
-
Rhea-AI Summary

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on May 16, 2024. The event will be live webcasted on the company's website, with a replay available for a time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
Rhea-AI Summary

Syndax Pharmaceuticals reported its first-quarter financial results for 2024, highlighting the NDA filing for revumenib and BLA filing for axatilimab with Priority Reviews. The Company anticipates significant milestones with pivotal data from the AUGMENT-101 trial and potential approvals in the third quarter. The CEO emphasized the value-creating potential of launching innovative therapies into multi-billion-dollar markets. Syndax continues to focus on building a strong team for successful commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Summary

Syndax Pharmaceuticals granted inducement awards to six new employees to purchase up to 100,600 shares of common stock under the 2023 Inducement Plan. The stock options will vest over four years, with gradual vesting conditions tied to the employees' continued service relationship.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
-
Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) will announce its first quarter 2024 financial results and provide a business update on May 8, 2024. The company will host a conference call and webcast to discuss the financial results and business progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) CEO to participate in fireside chat at Stifel 2024 Virtual Targeted Oncology Forum. The event will be held on April 17, 2024, at 11:00 a.m. ET. Investors can access the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) presents positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory acute leukemia at the ASPHO Conference. The data highlights impressive activity and consistency with the adult population, showcasing a complete remission rate of 23% and an overall response rate of 46%. The safety profile of revumenib remains favorable, with no treatment-related discontinuations or dose reductions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) grants inducement awards to new employees, offering up to 164,200 shares of common stock under the 2023 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals completes enrollment in pivotal trial for revumenib in mutant nucleophosmin acute myeloid leukemia, with topline data expected in 4Q24 potentially supporting sNDA filing in 1H25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
none

FAQ

What is the current stock price of Syndax Pharmaceuticals (SNDX)?

The current stock price of Syndax Pharmaceuticals (SNDX) is $12.92 as of April 22, 2025.

What is the market cap of Syndax Pharmaceuticals (SNDX)?

The market cap of Syndax Pharmaceuticals (SNDX) is approximately 974.9M.

What is Syndax Pharmaceuticals Inc?

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative combination therapies for cancer and immune-related conditions.

What are the company’s primary product candidates?

Key candidates include revumenib, an oral menin inhibitor for treating acute leukemias, and axatilimab (marketed as Niktimvo), a monoclonal antibody targeting CSF-1R for chronic graft-versus-host disease.

How does revumenib work?

Revumenib targets the menin-KMT2A interaction, a critical pathway in leukemogenesis, thereby interfering with the progression of acute leukemias such as those characterized by KMT2A rearrangements or mutant NPM1.

What distinguishes axatilimab in treatment?

Axatilimab is designed to block the CSF-1 receptor, reducing inflammation and fibrosis associated with chronic graft-versus-host disease, especially in patients with limited options after multiple therapies.

How does Syndax generate revenue?

The company leverages a multifaceted business model that includes strategic partnerships, innovative funding agreements like synthetic royalty financing, and building a commercial-ready infrastructure for its therapies.

What role do clinical trials play in their strategy?

Clinical trials are central to Syndax’s strategy, aiding in the evaluation of efficacy and safety for its product candidates while supporting regulatory submissions and reinforcing the company's scientific credibility.

How does Syndax ensure scientific expertise and trustworthiness?

Syndax emphasizes rigorous clinical research, partnerships with leading academic and clinical institutions, and adherence to high regulatory standards, thereby showcasing its deep industry expertise and commitment to patient safety.

What makes Syndax unique in a competitive market?

Its focus on addressing key molecular pathways in cancer through specialized therapies, combined with robust clinical data and strategic commercial partnerships, sets Syndax apart as an innovative player in the biopharmaceutical sector.
Syndax Pharmaceuticals Inc

Nasdaq:SNDX

SNDX Rankings

SNDX Stock Data

974.88M
84.96M
1.3%
116.29%
22.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM